ABOUT COGNIZANT
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain. Our services and products, including the Cognizant® Shared Investigator Platform (SIP), are digitizing interactions between sponsors and investigators across every phase, helping the industry subtract time from clinical development and add it to patient lives.
Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world.
To learn more, visit cognizant.com/us/en/industries/life-sciences-technology-solutions
VIDEOS
Uncover how this shared investigator platform optimizes resource allocation and ensures a more agile and responsive clinical research environment.
Missy MacPhail, Executive Director of Business Development at Alliance for Multispecialty Research, LLC shares her experience with SIP and how it's benefited AMR.
Overcome obstacles associated with collaboration that, when left unaddressed, lead to site selection and patient enrollment issues for sponsors and operational challenges for sites.
Industry experts share their perspectives on end-to-end clinical development, essential elements of a unified clinical platform, as well as the associated benefits and challenges involved.
View this webinar to find out how the Cognizant® Shared Investigator Platform (SIP) automates the flow of documents connecting sponsor eTMF systems while enhancing site-sponsor collaboration, compounding efficiencies, and accelerating trials.
As clinical trials grow more complex, stakeholders urgently need to improve clinical trial efficiencies. Explore a solution for virtual monitoring, study oversight, and document exchange and collaboration, that enables sites, sponsors, and CROs to adapt to the new normal of conducting clinical trials virtually.
The Cognizant Shared Investigator Platform (SIP) supports a new, site-first approach for streamlining clinical trial processes. The industry’s first single-instance, multi-tenant SaaS solution, Cognizant SIP provides investigators and sponsors with a single technology platform from which they can collaborate and share documents, and harmonize workflows across the clinical trial lifecycle.
This Shared Investigator Platform (SIP) is a multi-sponsor collaborative solution for clinical trial site selection, start-up communications, and management designed to simplify and accelerate clinical trials by eliminating redundant work for sponsors and clinical sites.
Seven of the top fifteen global biopharmaceutical companies are on a single clinical technology platform, leveraging one environment, operating via common workflows, documents and training.
Discover how 7 of the top 15 global biopharmaceutical companies came together on a single clinical technology platform and operated through common workflows and common trial documents.
CONTACT INFORMATION
Cognizant Technology Solutions
Glenpointe Centre West 500 Frank W Burr Blvd
Teaneck, NJ 07666
UNITED STATES
Phone: +1 201-310-2499
Contact: Kavitha Lokesh
BROCHURES
- SIP Simplifies Collaboration Between Sites And Sponsors
- Transform Clinical Trials With Cognizant SIP: Efficient, Collaborative, Virtual
- The Cognizant® Shared Investigator Platform (SIP) Document Exchange Module
- Optimize Your Safety Notification Process With The Cognizant SIP Safety Exchange Module
- Seamlessly Connect Sponsor eTMF Systems And The Florence eISF
- Cognizant® Shared Investigator Platform Video Meetings
- Modernize Operations To Support A New Way Forward For Clinical Trials With Cognizant® SIP
FEATURED ARTICLES
-
![iStock-1002126898-graph-tablet-meeting-risks-planning]( "How A Dedicated Medical Affairs Team Drives Site Engagement")
Learn about the improvements made to SIP, which have allowed for quick access to study documents and bulk actions for streamlined document management and enhanced user experience.
-
![iStock-1206796363-ai-artificial-intelligence-machine-learning-technology]( "Using AI To Speed And Simplify Site Validation")
Sites that lack the proper skills and staff can delay the delivery of drugs to the market. Discover how site validation can be improved by combining qualitative and quantitative data.
-
![gettyimages1350791957]( "Streamlined Feasibility: Unlocking The Site-Sponsor Relationship")
Determining the feasibility of a site for clinical research is a critical component of the entire trial process. Discover how automation and standardization can improve the site-sponsor journey.
-
![DNA GettyImages-513751816]( "Adoption Remains Strong For Cognizant® Shared Investigator Platform")
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain.
-
![GettyImages-547418608-lab-team-collaboration-planning]( "Site And Sponsor Harmonization For Speedy Startups, Monitoring")
Now more than ever, stakeholders need harmony among their disparate systems — and that starts with the right organizational mindset: a culture of connectivity. Here’s what experts recommend.
-
![clinical staff (002)]( "Clinical Trials Separate The Signal From The Noise")
Hear about the trajectory and growth of the Shared Investigator Platform, the history and impact of biomarkers in clinical trial conduct, and the personal insights from Avi Kulkarni's 30-year career.
-
![Clinical Supply Forecasting And Planning]( "Roche Cuts Feasibility Process By 36%")
Uncover how an industry pioneer and veteran biotech benefited from this solution after struggling with complexity and consistency when it came to its approach to clinical trial feasibility.
-
![iStock-1251299015-lab-scientist-research-microscope]( "Growth Remains Strong For Shared Investigator Platform In 2021")
Cognizant SIP has maintained its growth momentum in 2021 as research sites have continued their adoption of the platform at a steady pace.
-
![cognizantebook]( "SIP Support For The “New Normal” In The COVID-19 Crisis")
In the “New Normal,” Sponsors and sites collaborate remotely throughout the trial lifecycle by leveraging a solution that streamlines trial set-up and execution, leading to improved site experiences and faster time-to-market.
-
![iStock-1196710425-450]( "It’ll Take New Tools And Partnerships To Fast-Track Clinical Trials For A COVID-19 R<sub>X</sub>")
The industry needs new tools, technologies, and partnerships to collaborate virtually on clinical trials for COVID-19 treatments.
-
![Coronavirus vaccine, syringe COVID 19]( "Agile Drug Development Required In A New Age Of Urgency")
Why it’s time to reconsider the current drug development paradigm. Complementing traditional RCTs with accelerated RWE studies and real-time clinical analysis provides true benefits.
